Assembly生物 ASMB 深 沪
等待开盘 02-07 09:30:00 美东时间
26.125
+0.735
+2.89%
华盛通- 最 高36.50
- 今 开25.62
- 成交量 2.87万股
- 最 低 24.675
- 昨 收 25.39
- 总市值 125.97万
- 52周最高 39.705
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 7.75
- 委 比 99.08%
- 总股本 4.82万
- 历史最高 67.65
- 量 比 0.24
- 振 幅 46.57%
- 历史最低 0.59
- 每 手 1
- 风险率 8.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes
Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activity and weekly oral dosing potential.
2025-12-23 02:46
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
Assembly Biosciences' CEO, Jason Okazaki, and CMO, Anuj Gaggar, will participate in a fireside chat at the Jefferies 2025 Global Healthcare Conference on June 4, 2025. The event will be live streamed and available for replay on the company's website.
2025-05-27 20:05
HC Wainwright & Co. Reiterates Neutral on Assembly Biosciences
HC Wainwright & Co. analyst Ed Arce reiterates Assembly Biosciences (NASDAQ:ASMB) with a Neutral.
2024-09-24 18:44
Assembly Biosciences' Investigational Herpes Treatment Shows Antiviral Efficacy, Safety In Healthy Participants
Assembly Biosciences reported interim results from its Phase 1a study of ABI-5366, a long-acting HSV inhibitor for recurrent genital herpes. The drug showed a favorable safety profile and achieved target plasma concentrations for antiviral efficacy.
2024-09-24 01:39
Jefferies Upgrades Assembly Biosciences to Buy, Raises Price Target to $35
Jefferies analyst Dennis Ding upgrades Assembly Biosciences (NASDAQ:ASMB) from Hold to Buy and raises the price target from $2 to $35.
2024-09-20 20:24
